Janux Q2 net loss $17.5M; cash $303.3M; Nasdaq compliance regained

Janux Therapeutics, Inc.

2023-Q2 EPS reported -$0.84 revenue$3,105,000

Net loss of $17.5M for Q2 2023 vs. $16.9M in Q2 2022; R&D expense $14.9M, G&A $6.9M.
Cash, cash equivalents & short-term investments of $303.3M at June 30, 2023; July offering raised ~$60M gross.
PSMA-TRACTr JANX007 Phase 1 data showed meaningful PSA drops with manageable safety/CRS profile.
Nasdaq compliance regained after Ron Barrett, Ph.D. became independent director; matter closed.
Appointed Dr. Zachariah McIver as VP, Clinical Development; he brings >15 years bispecific experience.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Janux Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income a net loss of $17.5 million.

Period: the second quarter ended June 30, 2023
Net income: a net loss of $17.5 million
Result: reported results

Exact text from the filing

Janux Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three and six months ended June 30, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Janux Therapeutics, Inc. reported financial results for the six months ended June 30, 2023.

Period: the six months ended June 30, 2023
Result: reported results

Exact text from the filing

Janux Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three and six months ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039843

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.